An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Durvalumab is a programmed death-ligand 1 (PD-L1) inhibitor with clinical activity in advanced urothelial cancer (AUC) 1 . AUC is characterized by several recurrent targetable genomic alterations 2 – 5 . This study ( NCT02546661 , BISCAY) combined durvalumab with relevant targeted therapies in bioma...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2021-05, Vol.27 (5), p.793-801
Hauptverfasser:	Powles, Thomas, Carroll, Danielle, Chowdhury, Simon, Gravis, Gwenaelle, Joly, Florence, Carles, Joan, Fléchon, Aude, Maroto, Pablo, Petrylak, Daniel, Rolland, Frédéric, Cook, Natalie, Balar, Arjun V., Sridhar, Srikala S., Galsky, Matthew D., Grivas, Petros, Ravaud, Alain, Jones, Robert, Cosaert, Jan, Hodgson, Darren, Kozarewa, Iwanka, Mather, Richard, McEwen, Robert, Mercier, Florence, Landers, Dónal
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase 692/699/67/1059 692/699/67/589 Adenosine diphosphate Antibodies, Monoclonal - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - antagonists & inhibitors Benzamides - therapeutic use Biological markers Biomarkers Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Biomedical and Life Sciences Biomedicine Bladder cancer Cancer Cancer Research Chemotherapy Deoxyribonucleic acid DNA DNA repair Drug therapy Fibroblast growth factor receptors Gene mutations Genetic aspects Genomics Growth factors Homologous recombination Homologous recombination repair Homology Humans Immunotherapy Infectious Diseases Inhibitors Letter Mechanistic Target of Rapamycin Complex 1 - antagonists & inhibitors Mechanistic Target of Rapamycin Complex 1 - genetics Mechanistic Target of Rapamycin Complex 2 - antagonists & inhibitors Mechanistic Target of Rapamycin Complex 2 - genetics Metabolic Diseases Metastases Metastasis Molecular Medicine Molecular targeted therapy Molecular Targeted Therapy - methods Monoclonal antibodies Morpholines - therapeutic use Neurosciences Oncology, Experimental PD-L1 protein Phosphatidylinositol 3-Kinases - genetics Phthalazines - therapeutic use Piperazines - therapeutic use Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors Poly (ADP-Ribose) Polymerase-1 - genetics Poly(ADP-ribose) polymerase Progression-Free Survival Pyrimidines - therapeutic use Receptors, Fibroblast Growth Factor - antagonists & inhibitors Receptors, Fibroblast Growth Factor - genetics Ribose Safety engineering Survival Targeted cancer therapy TOR protein TOR Serine-Threonine Kinases - genetics Tumors Urinary tract cancer Urologic Neoplasms - drug therapy Urologic Neoplasms - genetics Urologic Neoplasms - pathology Urothelial cancer Urothelial carcinoma Urothelium - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!